News coverage about AVEO Pharmaceuticals (NASDAQ:AVEO) has trended somewhat positive recently, according to Accern. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. AVEO Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 48.4853259561468 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news articles that may have effected Accern’s rankings:
- BRIEF-Aveo Quarterly Loss Per Share $0.08 (reuters.com)
- AVEO Pharmaceuticals (AVEO) Q4 Loss Wider, Revenues Miss (finance.yahoo.com)
- AVEO Reports Full Year 2017 Financial Results and Provides Business Update (finance.yahoo.com)
- AVEO posts 4Q profit (finance.yahoo.com)
- AVEO Pharmaceuticals, Inc. (AVEO) estimated to achieve EPS growth of -44.10% for this year – Wallstreet Investorplace (wallstreetinvestorplace.com)
AVEO has been the subject of a number of research analyst reports. B. Riley reiterated a “buy” rating and issued a $5.00 target price on shares of AVEO Pharmaceuticals in a research report on Tuesday, January 16th. Zacks Investment Research upgraded shares of AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. BidaskClub downgraded shares of AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, January 9th. Finally, initiated coverage on shares of AVEO Pharmaceuticals in a research report on Wednesday, November 15th. They issued a “buy” rating and a $5.00 target price for the company. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $4.05.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.